|
To listen to individual tracks now, click the  icon. To download tracks to a CD, right-click the icon for your preferred file type. Files are provided in WMA for users with Windows Media Player or  MP3 for users with other audio players.
|
| Track 1 |
Introduction by Neil Love, MD |
|
|
| Track 2 |
Combined analysis of NSABPB-
31 and NCCTG-N9831
(Dr Romond) |
|
|
| Track 3 |
BCIRG 006 clinical trial results
(Dr Slamon) |
|
|
| Track 4 |
Results of the HERA trial
(Dr Leyland-Jones) |
|
|
| Track 5 |
Results of Intergroup trial
NCCTG-N9831 (Dr Kaufman) |
|
|
| Track 6 |
Cardiac safety data from
NSABP-B-31 (Dr Geyer) |
|
|
| |
|
|
|
 |
Dennis J Slamon, MD, PhD
Professor of Medicine
Chief, Division of Hematology/Oncology
Director of Clinical/Translational Research
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California
Conducted on September 17, 2005
Click here to download the entire interview |
WMA |
MP3 |
|
| Track 1 |
Introduction by Neil Love, MD |
|
|
| Track 2 |
Overview of recent results of
adjuvant trastuzumab trials |
|
|
| Track 3 |
Efficacy of trastuzumab/carboplatin/docetaxelTCH arm
in BCIRG 006 |
|
|
| Track 4 |
BCIRG 006: Cardiac safety data |
|
|
| Track 5 |
Selecting an adjuvant regimen
for patients with HER2-positive
disease |
|
|
| Track 6 |
Controversies in HER2 testing |
|
|
| Track 7 |
Trastuzumab monotherapy in the
adjuvant setting |
|
|
| Track 8 |
Duration and sequencing of
adjuvant trastuzumab therapy |
|
|
| Track 9 |
Delayed adjuvant trastuzumab |
|
|
| Track 10 |
Predictors of response to adjuvant
trastuzumab |
|
|
| Track 11 |
Management of patients who
progress following adjuvant
trastuzumab |
|
|
| Track 12 |
Combining adjuvant trastuzumab
with hormonal therapy |
|
|
| Track 13 |
Combining trastuzumab with
chemotherapy in the metastatic
setting |
|
|
| Track 14 |
Selecting a chemotherapy
regimen to combine with
trastuzumab |
|
|
| Track 15 |
Combining trastuzumab and
bevacizumab |
|
|
| Track 16 |
CNS metastases in patients
receiving adjuvant trastuzumab |
|
|
| Track 17 |
Research strategies with lapatinib |
|
|
| Track 18 |
Perspectives on neoadjuvant
trastuzumab |
|
|
| |
|
|
|
 |
Norman Wolmark, MD
Professor and Chairman, Department of Human Oncology
Allegheny General Hospital
Professor, Drexel University College of Medicine
Chairman, National Surgical Adjuvant Breast and Bowel Project
Pittsburgh, Pennsylvania
Conducted on September 18, 2005
Click here to download the entire interview |
|
|
|
| Track 1 |
Introduction by Neil Love, MD |
|
|
| Track 2 |
Background for the combined
NSABP/NCCTG analysis |
|
|
| Track 3 |
Incorporation of the adjuvant
trastuzumab trial results into
clinical practice |
|
|
| Track 4 |
Clinical use of adjuvant trastuzumab
in elderly patients |
|
|
| Track 5 |
Concurrent versus sequential
adjuvant trastuzumab and
chemotherapy |
|
|
| Track 6 |
Delayed adjuvant trastuzumab |
|
|
| Track 7 |
Impact of adjuvant trastuzumab
on distant disease-free survival |
|
|
| Track 8 |
Impact of the risk of relapse on
management of patients with
HER2-positive, node-negative
disease |
|
|
| Track 9 |
Future adjuvant trials combining
bevacizumab with trastuzumab
in patients with HER2-positive
disease |
|
|
| Track 10 |
Clinical use of adjuvant docetaxel/
carboplatin/trastuzumab |
|
|
| Track 11 |
Adjuvant trastuzumab for patients
with reduced ejection fraction
following AC |
|
|
| Track 12 |
NSABP neoadjuvant trastuzumab
trial |
|
|
| Track 13 |
Use of adjuvant trastuzumab prior
to the release of the trial results |
|
|
| Track 14 |
Combining trastuzumab with
other biologic agents |
|
|
| Track 15 |
Clinical trial concept of trastuzumab
plus bevacizumab |
|
|
| Track 16 |
Disease-free survival as the
primary endpoint for adjuvant
trials |
|
|
| Track 17 |
Cardiac safety analysis in the
adjuvant trastuzumab trials |
|
|
| Track 18 |
Clinical trials mechanisms |
|
|
| Track 19 |
Perspectives on future directions
in clinical research |
|
|
|
| Track 1 |
Introduction by Neil Love, MD |
|
|
| Track 2 |
Evolution of the HERA trial design |
|
|
| Track 3 |
Efficacy results of the HERA trial |
|
|
| Track 4 |
Cardiac toxicity observed in the
HERA trial |
|
|
| Track 5 |
Concurrent versus sequential
adjuvant trastuzumab |
|
|
| Track 6 |
Implications of BCIRG 006
clinical trial results |
|
|
| Track 7 |
Incorporating adjuvant trastuzumab
into clinical practice |
|
|
| Track 8 |
Clinical use of trastuzumab with
hormonal therapy |
|
|
| Track 9 |
Delayed adjuvant trastuzumab in
patients with high-risk disease |
|
|
| Track 10 |
Combining adjuvant trastuzumab
with dose-dense chemotherapy |
|
|
| Track 11 |
Future research strategies in
patients with HER2-positive
disease |
|
|
| Track 12 |
Clinical trials of trastuzumab and
bevacizumab |
|
|
| Track 13 |
Neoadjuvant trastuzumab |
|
|
| Track 14 |
Reflections on progress in
targeted therapy in oncology |
|
|
|
|
